The Pallas laser is FDA cleared for the treatment of vitiligo, psoriasis, atopic dermatitis and leukoderma.

South Korea-based Laseroptek Co., Ltd. is launching the Pallas Solid-State 311nm UVB laser for the treatment of vitiligo, psoriasis, atopic dermatitis and leukoderma in the United States. 

Pallas allows the choice of either 308 or 311 nanometer versions.  Both wavelength choices eliminate the need for excimer gas and electrode replacements, providing a reduction in operating costs. Pallas is the fifth Laseroptek device to receive FDA clearance in the U.S. for dermatological treatments.

Gale Force Aesthetics is the exclusive distributor of Laseroptek lasers in the U. S. "We are excited and proud to partner with LASEROPTEK to launch Pallas in the U.S.  Physicians need safe and effective treatment options for difficult-to-treat skin conditions like vitiligo, psoriasis, atopic dermatitis and leukodermas. We are confident that this device will provide a much-needed option to physicians and deliver great results for patients," says Jayson Jonsson, CEO of Gale Force Aesthetics, in a news release.